Lucien Cuvelier, NPI/Business Development Manager, Abbott Laboratories
Thomas Muster, CEO & CSO, AVIR Green Hills Biotechnology AG
Jean-Jacques Bienaimé, CEO, BioMarin Pharmaceuticals Inc.
Jeremy Levin, Senior Vice President, Bristol-Meyers Squibb
Steve Dickman, CEO, CBT Advisors
Stephanie Léouzon, Managing Director, European Healthcare, Credit Suisse
Anne Ezendam, Director, Credit Suisse Asset Management
Dimitri F. Dimitriou, Chief Executive Officer, DyoDelta Biosciences
Dr Olivier Litzka, Partner – Life Sciences, Edmond de Rothschild Investment Partners
Dr Bryan Morton, CEO, EUSA Pharma Inc
Dr Christina Takke, Principal, Forbion Capital Partners
Arthur L Franken, Partner, Gilde Healthcare Partners
Jose Maria Romero*, Vice President Transactions, Late-Stage Projects Worldwide Business Development, GlaxoSmithKline
Dr Alexander Asam, Investment Advisor Private Equity Team, HBM Partners AG
Malcolm Weir, CEO, Heptares Therapeutics
Stan Yakatan, President, Katan Associates
Anthony Hartley, Executive Director Investment Banking, Lehman Brothers Europe Ltd
Dr Jörg Neermann, Partner, LSP
Roel Bulthuis, Venture Capital Scouting, Early Stage Licensing, Merck Serono International
Dr Christian Zahnd, CEO, Molecular Partners AG
David Lemus, CFO, Morphosys AG
Esteban Pombo Villar, Head of Strategic Alliance Management EU, Novartis Pharma AG
Reinhard J Ambros, Managing Director, Novartis Venture Fund
Sam Fazeli, Managing Director, Senior Biotechnology Analyst, Head of Equity Research, Piper Jaffray Ltd
Antoine Papiernik, Managing Partner, Sofinnova Partners
Michael Gilman, CEO, Stromedix
Dr Yvonne Gunsch-Wegmann, Vice President, Head of Issuers & Investor Relations, SWX
Swiss Exchange
Malcolm Bates, Partner, Taylor Wessing
Alexandra Goll, General Partner, TVM Capital
Dr Simon Turton, Managing Director, Warburg Pincus
*to be confirmed